First estimates of the potential cost and cost saving of protecting childhood hearing from damage caused by Congenital CMV infection

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 100, Issue 6, 2015, Pages F501-F506

  Williams, Eleri J ^a,b,c   Gray, Joanne ^d   Luck, Suzanne ^e,f   Atkinson, Claire ^e   Embleton, Nicholas D ^b,c   Kadambari, Seilesh ^g   Davis, Adrian ^h   Griffiths, Paul ^e   Sharland, Mike ^g   Berrington, Janet E ^b,c   Clark, Julia E ^a,i,j  

^a Infectious Diseases Allergy   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NORTHUMBRIA UNIVERSITY   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f KINGSTON HOSPITAL   (United Kingdom)

^g ST GEORGE S HOSPITAL   (United Kingdom)

^h PUBLIC HEALTH ENGLAND   (United Kingdom)

ⁱ LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^j UNIVERSITY OF QUEENSLAND   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VALGANCICLOVIR;

ARTICLE; CLINICAL ARTICLE; CONGENITAL INFECTION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; CYTOMEGALOVIRUS INFECTION; FOLLOW UP; HEALTH CARE COST; HEARING; HEARING TEST; HUMAN; INFANT; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PERCEPTION DEAFNESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UNITED KINGDOM; COMPLICATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ECONOMICS; FEMALE; HEARING LOSS, SENSORINEURAL; ISOLATION AND PURIFICATION; MALE; NEWBORN; NEWBORN SCREENING; PROCEDURES;

COST SAVINGS; COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENGLAND; FEMALE; HEARING LOSS, SENSORINEURAL; HEARING TESTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEONATAL SCREENING;

EID: 84950143434     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/archdischild-2014-306756     Document Type: Article

References (34)

1. Peckham CS, Chin KS, Coleman JC, et al. Cytomegalovirus infection in pregnancy: preliminary findings from a prospective study. Lancet 1983;1:1352-5.
2. Griffiths PD, Baboonian C, Rutter D, et al. Congenital and maternal cytomegalovirus infections in a London population. Br J Obstet Gynaecol 1991;98:135-40.
3. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007;17:355-63.
4. Pass RF. Congenital cytomegalovirus infection and hearing loss. Herpes 2005;12:50-5.
5. Barbi M, Binda S, Caroppo S, et al. A wider role for congenital cytomegalovirus infection in sensorineural hearing loss. Pediatr Infect Dis J 2003;22:39-42.
6. de Vries JJ, van Zwet EW, Dekker FW, et al. The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a populationbased prediction model. Rev Med Virol 2013;23:241-9.
7. Fowler KB, McCollister FP, Dahle AJ, et al. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 1997;130:624-30.
8. Dahle AJ, Fowler KB, Wright JD, et al. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audiol 2000;11:283-90.
9. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143:16-25.
10. Williams EJ, Kadambari S, Berrington JE, et al. Feasibility and acceptability of targeted screening for congenital CMV-related hearing loss. Arch Dis Child Fetal Neonatal Ed 2014;99:F230-6.
11. Kadambari S, Williams EJ, Luck S, et al. Evidence based management guidelines for the detection and treatment of congenital CMV. Early Hum Dev 2011;87:723-8.
12. Boppana SB, Ross SA, Shimamura M, et al. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med 2011;364:2111-18.
13. Boppana SB, Ross SA, Novak Z, et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA 2010;303:1375-82.
14. Yamamoto AY, Mussi-Pinhata MM, Marin LJ, et al. Is saliva as reliable as urine for detection of cytomegalovirus DNA for neonatal screening of congenital CMV infection? J Clin Virol 2006;36:228-30.
15. World Health Organization. UK WHO growth charts for boys aged 0-4 years. http://www.rcpch.ac.uk/system/files/protected/page/A4%20Boys%200-4YRS%20 (4th %20Jan%202013).pdf
16. NDCS. National Deaf Children's Society Information for families: Congenital cytomegalovirus and deafness. 2011. http://www.ndcs.org.uk/family-support/order-and-view-our-publications/congenital.rma?utm-campaign=Membership&utm-medium=login&utm-source=login (accessed 19 May 2014).
17. National Institute of Health and Clinical Excellence. Guide to the methods of technology appraisal. 2008. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed 3 Apr. 2013).
18. Uus K, Bamford J, Taylor R. An analysis of the costs of implementing the National Newborn Hearing Screening Programme in England. J Med Screen 2006;13:14-19.
19. Seymour CA, Thomason MJ, Chalmers RA, et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess 1997;1:i-iv, 1-95.
20. Simpson N, Anderson R, Sassi F, et al. The cost-effectiveness of neonatal screening for cystic fibrosis: an analysis of alternative scenarios using a decision model. Cost Eff Resour Alloc 2005;3:8.
21. Schroeder L, Petrou S, Kennedy C, et al. The economic costs of congenital bilateral permanent childhood hearing impairment. Pediatrics 2006;117:1101-12.
22. Barton GR, Bloor KE, Marshall DH, et al. Health-service costs of pediatric cochlear implantation: multi-center analysis. Int J Pediatr Otorhinolaryngol 2003;67:141-9.
23. Ramirez Inscoe JM, Nikolopoulos TP. Cochlear implantation in children deafened by cytomegalovirus: speech perception and speech intelligibility outcomes. Otol Neurotol 2004;25:479-82.
24. Lee DJ, Lustig L, Sampson M, et al. Effects of cytomegalovirus (CMV) related deafness on pediatric cochlear implant outcomes. Otolaryngol Head Neck Surg 2005;133:900-5.
25. Martinez-Cruz CF, Poblano A, Conde-Reyes MP. Cognitive performance of school children with unilateral sensorineural hearing loss. Arch Med Res 2009;40:374-9.
26. Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear 1998;19:339-54.
27. Oliver SE, Cloud GA, Sanchez PJ, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol 2009;46(Suppl 4):S22-6.
28. Stehel EK, Shoup AG, Owen KE, et al. Newborn hearing screening and detection of congenital cytomegalovirus infection. Pediatrics 2008;121:970-5.
29. Choi KY, Schimmenti LA, Jurek AM, et al. Detection of cytomegalovirus DNA in dried blood spots of Minnesota infants who do not pass newborn hearing screening. Pediatr Infect Dis J 2009;28:1095-8.
30. Kimberlin DW, Jester PM, Sanchez PJ. et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. NEJM 2015;132:933-43.
31. Townsend CL, Peckham CS, Tookey PA. Surveillance of congenital cytomegalovirus in the UK and Ireland. Arch Dis Child Fetal Neonatal Ed 2011;96:F398-403.
32. Istas AS, Demmler GJ, Dobbins JG, et al. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis 1995;20:665-70.
33. Nagy A, Endreffy E, Streitman K, et al. Incidence and outcome of congenital cytomegalovirus infection in selected groups of preterm and full-term neonates under intensive care. In Vivo 2004;18:819-23.
34. DePasquale JM, Freeman K, Amin MM, et al. Efficient linking of birth certificate and newborn screening databases for laboratory investigation of congenital cytomegalovirus infection and preterm birth: Florida, 2008. Matern Child Health J 2012;16:486-94.